评论：结果指标存在缺陷。 - Suppr | 超能文献

Commentary: Outcome measures were flawed.

作者信息

Ebers G C

机构信息

University of Oxford, John Radcliffe Hospital, Oxford OX39DU.

出版信息

BMJ. 2010 Jun 3;340:c2693. doi: 10.1136/bmj.c2693.

DOI:10.1136/bmj.c2693

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Commentary: Outcome measures were flawed.评论：结果指标存在缺陷。

BMJ. 2010 Jun 3;340:c2693. doi: 10.1136/bmj.c2693.

2

The multiple sclerosis risk sharing scheme.多发性硬化症风险分担计划。

BMJ. 2010 Jun 3;340:c2882. doi: 10.1136/bmj.c2882.

3

Commentary: Scheme has benefited patients.评论：该方案已使患者受益。

BMJ. 2010 Jun 3;340:c2707. doi: 10.1136/bmj.c2707.

4

Multiple sclerosis risk sharing scheme: a costly failure.多发性硬化症风险分担计划：代价高昂的失败。

BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.

5

Continuing the multiple sclerosis risk sharing scheme is unjustified.继续实施多发性硬化症风险分担计划是不合理的。

BMJ. 2010 Jun 3;340:c1786. doi: 10.1136/bmj.c1786.

6

Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.评估治疗多发性硬化症药物的共享方案：以具有成本效益的方式提供多发性硬化症的有效治疗。

BMJ. 2003 May 31;326(7400):1212. doi: 10.1136/bmj.326.7400.1212.

7

Cost effectiveness of multiple sclerosis drugs remains unknown.多发性硬化症药物的成本效益仍然未知。

BMJ. 2000 Aug 12;321(7258):399.

8

MS risk sharing scheme. Some clarification needed.多发性硬化症风险分担计划。需要一些澄清。

BMJ. 2010 Jul 7;341:c3589. doi: 10.1136/bmj.c3589.

9

Cost-effectiveness analyses of treatments for multiple sclerosis: are they clinically relevant?多发性硬化症治疗的成本效益分析：它们与临床相关吗？

Neurology. 2011 Jul 26;77(4):317-8. doi: 10.1212/WNL.0b013e318227066d. Epub 2011 Jul 20.

10

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: commentary.

Mult Scler. 2013 Jan;19(1):29-30. doi: 10.1177/1352458512470507.

引用本文的文献

1

Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations.疾病修正治疗缓解复发型多发性硬化症的成本效益分析中的建模方法：更新的系统评价和对未来经济评估的建议。

Pharmacoeconomics. 2018 Oct;36(10):1223-1252. doi: 10.1007/s40273-018-0683-9.

2

Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.多发性硬化症疾病修正疗法的成本效益：文献系统评价

Autoimmune Dis. 2012;2012:784364. doi: 10.1155/2012/784364. Epub 2012 Dec 6.